Axa
ANAB icon

Axa’s AnaptysBio ANAB Stock Holding History

Axa’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-39,600
Closed -$1.07M – 1164
2021
Q3 		$1.07M Hold
39,600
– – ﹤0.01% 957
2021
Q2 		$1.03M Buy
+39,600
New +$949K ﹤0.01% 997
2021
Q1 		– Sell
-95,354
Closed -$2.05M – 1202
2020
Q4 		$2.05M Sell
95,354
-20,446
-18% -$497K 0.01% 849
2020
Q3 		$1.71M Sell
115,800
-172
-0.1% -$3.1K 0.01% 846
2020
Q2 		$2.59M Buy
115,972
+61,800
+114% +$1.13M 0.01% 769
2020
Q1 		$765K Buy
+54,172
New +$822K ﹤0.01% 898
2019
Q4 		– Sell
-68,210
Closed -$2.39M – 1168
2019
Q3 		$2.39M Sell
68,210
-838
-1% -$39.9K 0.01% 823
2019
Q2 		$3.9M Sell
69,048
-20,364
-23% -$1.47M 0.02% 718
2019
Q1 		$6.53M Buy
89,412
+10,004
+13% +$691K 0.03% 566
2018
Q4 		$5.07M Buy
79,408
+9,825
+14% +$731K 0.02% 600
2018
Q3 		$6.94M Buy
69,583
+49,268
+243% +$4.09M 0.03% 576
2018
Q2 		$1.44M Buy
20,315
+258
+1% +$21.6K 0.01% 927
2018
Q1 		$2.09M Buy
+20,057
New +$2.26M 0.01% 850

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Axa's ANAB Position: Q4 2021 in Review

Axa sold out of AnaptysBio (ANAB) in Q4 2021, closing a stake of 39,600 shares — an estimated $1.07M sold.

Axa first reported a position in ANAB in Q1 2018 and held it in 13 quarters. The position peaked at $6.94M in Q3 2018. 136 funds tracked by Wall St. Rank hold ANAB as of Q4 2021.

  • Axa reported no remaining AnaptysBio position as of Q4 2021 after selling out during the quarter.
  • Axa sold 39,600 AnaptysBio shares in Q4 2021, an estimated $1.07M.
  • Axa first reported a position in AnaptysBio in Q1 2018 and held it in 13 quarters.
  • Axa's AnaptysBio position peaked at $6.94M in Q3 2018.
  • 136 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2021.

Based on Axa's 13F filing for Q4 2021, filed 14 Feb 2022.